Previous Article | Next Article ![]()
Journal of Bacteriology, November 1999, p. 6689-6696, Vol. 181, No. 21
Department of Biosciences and Institute of
Biotechnology, Viikki Biocenter, FIN-00014 University of Helsinki,
Finland
Received 1 February 1999/Accepted 18 May 1999
The double-stranded DNA bacteriophage PRD1 uses an IncP
plasmid-encoded conjugal transfer complex as a receptor. Plasmid
functions in the PRD1 life cycle are restricted to phage adsorption and DNA entry. A single phage structural protein, P2, located at the fivefold capsid vertices, is responsible for PRD1 attachment to its
host. The purified recombinant adsorption protein was judged to be
monomeric by gel filtration, rate zonal centrifugation, analytical
ultracentrifugation, and chemical cross-linking. It binds to its
receptor with an apparent Kd of 0.20 nM, and
this binding prevents phage adsorption. P2-deficient particles are unstable and spontaneously release the DNA with concomitant formation of the tail-like structure originating from the phage membrane. We
envisage the DNA to be packaged through one vertex, but the presence of
P2 on the other vertices suggests a mechanism whereby the injection
vertex is determined by P2 binding to the receptor.
Virus-cell interactions are
specific. The first step in virus propagation is the attachment to the
cell via recognition of and binding to the receptor structure. Virus
receptors consist of cellular surface components that interact with the
receptor binding protein, the virus-encoded counterpart of a receptor. This interaction then leads to the delivery of the viral nucleic acid
into the cell cytoplasm. A substantial amount of information is
available on the initial steps of bacteriophage infection of Escherichia coli T-like and filamentous phages. In tailed
phages (like T1, T4, and T5), the tail proteins form a channel spanning either the outer membrane or all envelope layers of the gram-negative cell and this channel is used to inject the genome while the capsid is
left outside (for a review, see reference 22). In
filamentous phages (fd), the major capsid protein is inserted into the
membrane, forming a pore (reviewed in reference 22).
Enveloped bacteriophages with virion structure analogous to that of the
enveloped viruses of higher organisms exhibit entry mechanisms
different from that of the DNA phages, as the entire virion (or a
substructure) is internalized by the process of membrane fusion
(6, 44). However, the entry mechanism of bacteriophages with
a membrane as an internal component of the virion most probably
exhibits a novel system for the DNA delivery.
The broad-host-range double-stranded DNA (dsDNA) bacteriophage PRD1,
capable of infecting a variety of gram-negative bacteria, is composed
of an icosahedral outer protein capsid and an internal membrane
(2, 7, 41). The membrane vesicle encloses the 14,925-bp-long
linear dsDNA genome (9, 15). The phage genome contains
inverted terminal repeats at both ends (48) and a covalently linked protein at each 5' terminus (4, 5). The DNA is
replicated by a phage-encoded polymerase via a protein-priming
mechanism (16, 49). The protein coat is composed of the
major capsid protein P3 organized on a pseudo T = 25 lattice
(15). The fivefold vertices are built up by a spike
structure comprised of three proteins, P31, P5, and P2 (45).
There are a number of intriguing functional and structural similarities
between PRD1 and adenovirus. These include genome organization and
replication strategy, capsid organization, and major coat protein fold,
as well as the structure and function of the fivefold receptor binding
structure (10, 15, 45, 46, 50). In this context, it should
be noted that phage PRD1 protein P2 is the structural equivalent of the
adenovirus receptor binding spike knob (protein PIV distal domain)
(52). For a detailed description of the PRD1 system, see the
review by Bamford et al. (3).
PRD1 infects cells harboring a conjugative plasmid, such as IncP
plasmid RP4 (43). Plasmid functions are only involved in host cell recognition and DNA penetration (21, 35). The
plasmid encodes the phage receptor complex, a cell envelope structure bridging the inner and outer membranes (25). Receptor
saturation experiments suggest that there are approximately 25 and 60 receptors per cell in E. coli and Salmonella
typhimurium, respectively (20, 30). This IncP-encoded
multiprotein structure functions also as a mating pair formation
complex-DNA transfer apparatus in bacterial conjugation (32, 42,
55).
Isolation and analysis of phage nonsense mutants revealed that PRD1
adsorption is dependent on one phage-specific structural protein, P2
(36, 37). P2 is a minor protein, the copy number being about
10 per virion (21, 36). In addition, at least three other
phage structural proteins (P11, P16, and P18) are involved in the DNA
entry (37). In wild-type virus, a tubular tail-like
structure, derived from the viral membrane and protruding through one
vertex, has been reported (15, 33). Tail formation is
dependent on at least protein P18, since a mutation in the corresponding gene prevents tube formation (2). Here we show that purified recombinant P2 is a monomeric protein able to interfere with the binding of the virus to its receptor. It is also a stability factor that secures that the DNA injection process does not start before the virus binds to its receptor. A novel DNA ejection mechanism is proposed involving the formation of the tail tube at the vertex that
binds to the receptor.
Bacteria, plasmids, and phages.
The bacterial strains used
in this study were E. coli K-12 HMS174 (F
0021-9193/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Stable Packaging of Phage PRD1 DNA Requires
Adsorption Protein P2, Which Binds to the IncP Plasmid-Encoded
Conjugative Transfer Complex
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
recA hsdR) (18) and JE2571 (leu thr thi
lacY thy pil) (13) and S. typhimurium LT2
DB7154 (supD) (36), DB7156 (supF)
(36), DS88 (8), PSA (supE)
(36), and SL5676 (
H2 H1-i::Tn10
[Tcs] non rev; B. A. D. Stocker,
Stanford University, Palo Alto, Calif.). Cells were grown in
Luria-Bertani (LB) medium (47). When appropriate, ampicillin
(100 µg/ml) and/or chloramphenicol (10 µg/ml) were added. Phage
PRD1 (41) was propagated on S. typhimurium DS88, and its mutant derivatives sus1 (36),
sus170 (36), and sus539 (45) were propagated on the suppressor strains PSA(pLM2),
DB7154(pLM2), and DB7156(pLM2), respectively. For the production of
wild-type and mutant phage particles, DS88 cells were infected at a
multiplicity of infection of about 5. After lysis, the particles were
concentrated and purified by rate zonal sucrose gradient
centrifugation, as previously described (8). The virus zones
from the sucrose gradients were further purified by ion-exchange
chromatography on MemSep cartridges (Millipore) as described by Walin
et al. (53). 14C-labeled wild-type and mutant
(sus170) PRD1 viruses were produced and purified as
described by Kotilainen et al. (30). The phage particles
from the lysate were concentrated and purified in sucrose gradients.
Two virus zones, containing empty (DNA-less) or filled (DNA-containing)
particles, were collected. The specific activities obtained were
2.0 × 105 and 2.4 × 105 cpm/µg of
protein for empty and DNA-containing wild-type particles, respectively,
and 1 × 105 cpm/µg for the DNA-containing
sus170 mutant particles. The plasmids and phages used are
listed in Table 1.
TABLE 1.
Plasmids and phages used in this study
Cloning of gene II.
Standard molecular cloning
techniques were performed as described by Sambrook et al.
(47). The coding sequence for PRD1 gene II (for
nucleotide numbering, see reference 9) was amplified by PCR and inserted into plasmid pMS470
8, resulting in plasmid pMG59. For the cloning strategy, see Table 1. The plasmid construct contains the strong controllable Ptac promoter
and the ribosome binding site of phage T7 gene 10 (23).
Expression and purification of protein P2.
E. coli
HMS174(pMG59) cells were grown in LB medium containing ampicillin at
37°C to a density of about 2 × 108 CFU/ml.
Synthesis of protein P2 was induced by the addition of isopropyl-
-D-thiogalactopyranoside to a final
concentration of 1 mM, and the cells were incubated for another 3 h at the same temperature. Bacteria were collected (Sorvall GS3 rotor,
5,000 rpm, 15 min, 5°C) and resuspended in 1/50 of the original
culture volume of 50 mM Tris-HCl, pH 7.4. After freezing at
20°C
and thawing, bacteria were disrupted by three passages through a French pressure cell (15,000 lb/in2). Urea was added to a final
concentration of 1 M, and the cell debris was removed by centrifugation
(Sorvall SS-34 rotor, 12,000 rpm, 20 min, 5°C). The supernatant was
further cleared by centrifugation (Sorvall T865 rotor, 25,000 rpm,
3 h, 10°C). To the resulting supernatant, saturated ammonium
sulfate was added to 25% saturation, and the precipitated proteins
were collected (SS-34 rotor, 10,000 rpm, 30 min, 5°C). The pellet was
resuspended in 50 mM Tris-HCl (pH 8.2)-50 mM NaCl and dialyzed
overnight in the cold against the same buffer, with several changes.
After clearing of the solution (SS-34, 10,000 rpm, 10 min, 5°C),
proteins were loaded at a flow rate of 1 ml/min onto a Source 15Q
column (Pharmacia) that had been equilibrated with the same buffer.
Bound proteins were eluted by a linear NaCl gradient up to 1 M. Fractions containing P2, as determined by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), were pooled and
dialyzed overnight in the cold against 50 mM potassium phosphate, pH
7.2, containing 12% ammonium sulfate. The solution, cleared as
described above, was loaded (0.5 ml/min) onto a phenyl-Superose HR 5/5
column (Pharmacia) equilibrated with the same buffer, and bound
proteins were eluted with a linear gradient of decreasing ammonium
sulfate concentrations. Fractions containing P2 were pooled, and the
proteins were precipitated by the addition of ammonium sulfate to 30%
saturation. After collection of the proteins by centrifugation as
described above, the pellet was resuspended in 50 mM Tris-HCl, pH 7.4, containing 150 mM NaCl, 1 M urea, and 1 mM 2-mercaptoethanol and P2 was
further purified by gel filtration on a Hi-Load 16/60 Superdex 200 column (Pharmacia) equilibrated with the same buffer. Fractions
containing purified protein P2 were stored on ice.
20°C. One molar urea (in 50 mM Tris-HCl, pH 7.4) was
added to the thawed pellet, and the cells were broken by sonication
(Ultrasonics Ltd. Sonifier; eight bursts of 30 s with 90-s
intervals; the samples were placed on ice-water). The suspension was
cleared by centrifugation (SS-34 rotor, 10,000 rpm, 1 h, 5°C),
and proteins were precipitated by addition of saturated ammonium
sulfate to 25% saturation. Labeled protein P2 was purified as
described above, with the exception that the last gel filtration step
was omitted.
Determination of P2 monomeric status. Rate zonal centrifugation was carried out in 5 to 20% sucrose gradients made in 20 mM Tris-HCl (pH 7.4)-150 mM NaCl (Sorvall TH 641 rotor, 35,000 rpm, 24 h, 10°C). Hen egg white lysozyme (14 kDa; Boehringer), bovine serum albumin (67 kDa; Boehringer), and PRD1 P3 trimer (130 kDa) (51) were used as molecular mass markers. Gel filtration experiments were done with a Superdex 200 HR 10/30 column (Pharmacia) equilibrated with 50 mM Tris-HCl (pH 7.4)-150 mM NaCl. The molecular mass standards used were as described above. Cross-linking was performed with increasing concentrations (0.01 to 0.5%) of glutaraldehyde in 50 mM potassium phosphate buffer, pH 7.2. In order to minimize the formation of unspecific intermolecular cross-links, the protein concentration in the samples was adjusted to 0.4 mg/ml. After 2 h of incubation at 22°C, samples were prepared for and analyzed by SDS-PAGE. Sedimentation equilibrium experiments were performed in a Beckman Optima XL-I analytical ultracentrifuge (50Ti analytical rotor, 12,000 rpm, 4°C). P2 was diluted so that the loading concentrations were 0.5, 0.7, and 2 mg/ml. The distribution of the protein was determined by measuring the absorbance at 294, 297, and 301 nm over the cell radius. Data were analyzed by using the Origin computer program (Microcal Inc., Northampton, Mass.). A partial specific volume of 0.7232 ml/g and a monomer molecular mass of 63,821 Da were calculated from the known amino acid sequence of the protein (9).
Phage adsorption test. Cells were grown to the optimal adsorption phase (approximately 2 × 109 CFU/ml) (30) in LB medium. 14C-labeled PRD1 was adsorbed to the cells for 15 min at 22°C. Cells were then collected by centrifugation and washed twice with 0.5 ml of LB medium. Radioactivity in the supernatant and pellet fractions was measured by liquid scintillation counting.
The reversibility of phage binding was analyzed by using the adsorption test, except that a 30-min equilibration was allowed between the washing steps. In another set of experiments, cells were transferred into 50 mM Tris-HCl (pH 7.2)-0.1% glucose. 14C-labeled phages were added, reversibility was challenged by adding increasing concentrations of NaCl, and the incubation was continued for 15 min. The washing steps were carried out in the used NaCl concentrations.Inhibition of phage adsorption by protein P2. Cells were grown to the optimal adsorption phase as described above. A constant number of cells (2 × 108 CFU) and various amounts of P2 (cell lysate or purified protein; see above) were mixed in a volume of 70 µl and incubated for 30 min at 22°C. The ability of P2 to interfere with phage binding was determined either by phage plaque assay or by the phage adsorption test. (i) In the phage plaque assay, approximately 200 PFU was added to the cell-P2 mixture, which was incubated for 15 min at 22°C. Thereafter, cells were collected by centrifugation and the amount of free (nonadsorbed) phage particles was determined by plating the supernatant on S. typhimurium DS88 cells. (ii) In the adsorption test, 14C-labeled PRD1, at a multiplicity of infection of about 3, was added. After 15 min of incubation at 22°C, cells were collected by centrifugation and washed twice with LB medium. Radioactivity in the supernatant and pellet fractions was measured by liquid scintillation counting.
P2 binding assay. Cells (2 × 108 CFU) and increasing amounts of 35S-labeled protein P2 were mixed and incubated for 45 min at 22°C. Subsequently, cells were collected by centrifugation and the amounts of free and bound P2 were determined by measuring the radioactivity in the supernatant and pellet fractions.
P2 inactivation assays. Purified protein P2 (150 ng) was incubated for 15 min at different temperatures; this was followed by 10 min of equilibration to 22°C. Cells (2 × 108 CFU) were added, and the adsorption inhibition assay was performed as described above. The effect of denaturing agents on P2 activity was tested by incubating 75 ng of P2 in the presence of 8 M urea or 5 M guanidine hydrochloride (GuHCl) for 15 min at 22°C. After that, the concentration of the denaturing agent was diluted to 1/10 of the original value and the incubation was continued for 30 min. The activity of the preparation was measured by the adsorption inhibition assay.
Polyclonal antiserum. Polyclonal antibodies against protein P2 were raised by immunizing a rabbit at 20-day intervals. For the primary immunization, the antigen (about 400 µg) was emulsified with complete Freund's adjuvant. Incomplete adjuvant was used in the subsequent immunizations. The first two immunizations were done with a sample cut out as a single band from a preparative SDS-14% polyacrylamide gel. For the final booster, purified P2 was used as the antigen. The serum was collected 2 weeks after administration of the third booster, and its specificity was determined by immunoblotting as described below. Anti-P2 immunoglobulins G (IgGs) were purified from the serum by chromatography on a GammaBind G Sepharose column (Pharmacia) in accordance with the manufacturer's instructions.
The antiserum and the purified IgG fraction were tested for neutralization ability. Approximately 150 PFU was treated with antibody dilutions for 1 h at 22°C; this was followed by plating with S. typhimurium DS88 cells. The neutralization titer was the last antibody dilution giving 50% reduction in the plaque count. Radioimmunoprecipitation of 35S-labeled protein P2 was performed by using protein A Sepharose CL-4B (Pharmacia) as previously described (29). The preimmune serum and polyclonal antibodies directed against bacteriophage
6 protein P4 were used as
negative controls.
Virus aggregation tests. 14C-labeled wild-type PRD1 (about 10,000 cpm) or P2-deficient mutant sus170 (about 5,000 cpm) was incubated with serial antibody dilutions for 2 h at 22°C. Virus aggregates were collected by centrifugation, and the radioactivity in the supernatant and pellet fraction was measured by liquid scintillation counting. To test if purified P2 can block virion precipitation, anti-P2 IgGs (1:1,000 dilution) and serial P2 dilutions were incubated for 2 h at 22°C. After that, 14C-labeled wild-type PRD1 (10,000 cpm) was added and the incubation was continued for 1 h at 22°C. Virus aggregates were collected as described above. Virus aggregation was also verified by electron microscopy by using a JEOL 1200 EX electron microscope operating at 60 kV. PRD1 wild-type and mutant (sus1 and sus170) particles were incubated with anti-P2 IgGs (1:500 dilution) for 1 to 2 h at 22°C; this was followed by negative staining (1% potassium phosphotungstate, pH 6.5).
Disruption of phage particles. Purified wild-type PRD1 particles in 20 mM Tris-HCl (pH 7.2) or in 20 mM potassium phosphate (pH 7.2)-1 mM MgCl2 were treated with 2.5 M GuHCl for 30 min at 37°C (4). Samples were diluted 1:1 with the appropriate buffer and analyzed by rate zonal centrifugation in 10 to 40% sucrose gradients made in the same buffer (Sorvall TH 641 rotor, 30,000 rpm, 45 min, 20°C). Fractions (0.9 ml) were collected starting from the top by using a Piston Gradient Fractionator (BioComp Instruments, Inc.). Fractions were analyzed by SDS-PAGE and Western blotting as described below.
Stability analysis of P2-deficient phage particles. Affinity-purified DNA-containing wild-type and P2-deficient (sus170 or sus539) phage particles (3 mg of protein/ml) in 20 mM Tris-HCl (pH 7.4) or in 20 mM potassium phosphate (pH 7.2) were stored at 4°C. The viscosity of the preparation was monitored by visual inspection. The particles were also subjected, at appropriate intervals, to rate zonal sedimentation analysis through a linear 5 to 20% sucrose gradient, as well as to electron microscopy (see above). Due to high viscosity, the samples were digested with DNase I (50 µg/ml [final concentration]) for 40 min at 22°C prior to application to carbon-coated grids. The effect of the DNase digestion was also verified by agarose gel electrophoresis.
Analytical methods. SDS-PAGE was performed as described by Olkkonen and Bamford (39). Western blotting was done essentially as previously described (40), after transfer of the proteins from SDS-polyacrylamide gels onto a polyvinylidene difluoride membrane (Millipore). Protein concentrations were determined with Coomassie brilliant blue by using bovine serum albumin as a standard (12). N-terminal amino acid analysis of the purified protein was performed in a Beckman 890D sequencer after SDS-PAGE and blotting (9). Circular dichroism (CD) spectra were recorded in a Jasco J-720 spectropolarimeter using a 1-mm path-length cell at the temperatures indicated in each case. The protein concentration of the samples was adjusted to approximately 35 µg/ml in 20 mM Tris-HCl buffer, pH 7.4. Each spectrum, recorded at a scan rate of 20 nm/min, was the average of five scans. The background contribution due to the solvent was subtracted in each case. Triton X-114 phase separation was performed essentially as described by Bordier (11), with incubation for 15 min at 30°C. After centrifugation, the radioactivity in the water and Triton X-114 phases was measured by liquid scintillation counting.
| |
RESULTS |
|---|
|
|
|---|
Cloning of gene II and purification of the gene
product.
The adsorption of phage PRD1 to its receptor on the cell
surface is dependent on a single minor phage protein, P2 (21,
37). In order to more closely characterize protein P2, gene
II was cloned into plasmid pMS470
8. In this plasmid, a
high level of protein expression is enabled by the strong
Ptac promoter and the ribosome binding sequence
of phage T7 gene 10. The biological activity of the gene
II construct was verified by genetic complementation using
the PRD1 sus170 nonsense mutant, which is defective in P2. The complementation titer of PRD1 sus170 on cells containing
the gene II clone was nearly the same as that obtained when
the suppressor strain DB7154(pLM2) was used.
|
Purified protein P2 is a stable asymmetric monomer. To determine the apparent molecular mass of the isolated protein, P2 was first subjected to rate zonal centrifugation, gel filtration, and cross-linking. In sucrose gradients, P2 sedimented to a position corresponding to a molecular mass of about 40 kDa. Gel filtration experiments indicated a molecular mass of approximately 95 kDa. Incubation of the protein with increasing amounts of glutaraldehyde did not result in detectable cross-linking products (data not shown). Taken together, these results indicate that purified protein P2 is an asymmetric monomer. To confirm this, protein samples at three different concentrations were subjected to analytical ultracentrifugation. Sedimentation equilibrium experiments indicated that the concentration profiles could be fitted by a single-species model with apparent molecular masses of 63,152 ± 189 (0.5 mg/ml), 63,642 ± 276 (0.7 mg/ml), and 58,372 ± 406 (2 mg/ml) Da (Fig. 2).
|
-sheet, with only
about 20%
-helices. These values are in good agreement with those
obtained by the sequence-based secondary-structure prediction
(24).
|
Recombinant P2 is biologically active and has high affinity for its
receptor.
PRD1 infects various gram-negative bacteria containing a
receptor-encoding conjugative plasmid, such as IncP plasmid RP4
(14, 41, 43). The biological activity of recombinant P2 was
studied by using bacteria (S. typhimurium DS88) expressing
the phage receptor. The ability of P2 to bind to the receptor was
analyzed indirectly by determining its ability to interfere with phage
binding. If P2 occupies the receptor sites at the cell surface,
infective phage particles are not able to attach to the cells. This was measured as increasing radioactivity (14C-labeled PRD1) or
plaque count in the supernatant fraction. The activity of P2, both as
purified protein and in cell extracts, was tested and compared by using
the radioactive phage adsorption method. The amount of protein used was
adjusted on the basis of SDS-PAGE analysis. The two preparations were
equally active (data not shown), as was the 35S-labeled
protein (tested by the phage plaque assay). The stability of P2 was
monitored during its storage under different conditions. The protein
could be stored on ice for at least 3 months with no detectable loss of
activity. The biological activity of P2 was also preserved when it was
frozen at
20 or
80°C. Treatment with 8 M urea or 5 M GuHCl,
followed by subsequent dilution of the denaturing agent, did not
abolish the ability of P2 to interfere with phage adsorption (data not shown).
|
Stable DNA packaging is secured by protein P2.
Binding of a
phage by its adsorption protein to the host must trigger the next step
in the infection process. In order to study the role of protein P2 in
DNA release from the phage particle, we compared the stability of
DNA-containing wild-type and two P2-deficient mutant PRD1 particles
(sus170 and sus539) by monitoring the physical
properties of highly purified preparations. The wild-type virion
preparation did not show any increase in viscosity and displayed a
single sedimenting zone in rate zonal centrifugation, even after 3 weeks of storage at 4°C. Increasing viscosity was seen in both of the
mutant particle preparations, and it was detectable already a few hours
after virus purification. In rate zonal centrifugation experiments,
only a barely detectable virus zone was obtained with mutant particles
stored at 4°C overnight and practically all of the material was found
in the pellet due to aggregation. Electron microscopy of negatively
stained P2
particles revealed an increasing number of
empty particles with an extended tail structure (Fig.
5). The tails of adjacent particles had a
tendency to associate to form larger aggregates. The viscosity of the
preparations was abolished by DNase treatment, allowing electron
microscopy examination to be made, as well as showing that the cause of
viscosity in the preparations was the DNA released from the particles.
Electrophoresis of the DNase-treated preparations also confirmed the
sensitivity of the mutant particle DNA to DNase (data not shown). These
experiments were carried out in 20 mM Tris-HCl (pH 7.4) buffer. It was
found that the P2
particles were more stable in potassium
phosphate buffer (pH 7.2). They behaved the same as the wild-type
particles in rate zonal centrifugation assays, and no considerable
increase in viscosity was observed after 3 weeks of storage at 4°C.
|
Protein P2 is a virion surface component that signals to the phage membrane. P2 was used as the antigen to produce polyclonal antibodies in a rabbit. Both serum and purified IgGs were tested for the ability to recognize 35S-labeled P2. The recognition of the labeled protein could be detected by a radioimmunoprecipitation assay (0.5 µg of P2/100 µl, 1:50 serum or IgG dilution; data not shown). In Western blotting, the antigen could be detected at antibody dilutions as high as 1:20,000 (Fig. 6B). Both P2 antiserum and the purified IgG fraction recognized and inactivated the intact virus, the highest antibody dilution giving a 50% reduction in plaque count being 1:50 (virus concentration, 1.2 × 103 PFU/ml; data not shown).
|
mutant particles were purified, and the ability of
anti-P2 serum to aggregate these particles was tested in a
precipitation assay. In the purification of P2
particles,
potassium phosphate was used instead of Tris buffer (used for the
wild-type virus), as the integrity of the P2
virions was
maintained in phosphate but not in the Tris buffer (see above). Anti-P2
serum and IgGs aggregated wild-type virus particles at the high virus
concentration (5 × 109 PFU/ml) used, even at high
antibody dilutions, as shown in the 14C-labeled PRD1
precipitation assay (Fig. 6A). Under the same conditions, mutant
P2-deficient particles were not aggregated (Fig. 6A). Also, purified P2
blocked precipitation, confirming the specificity of the antiserum
(data not shown). Virus aggregation was also observed by electron
microscopy in samples containing wild-type and mutant (defective in DNA
packaging protein P9) PRD1 particles but not with mutant particles
devoid of the adsorption protein P2 (data not shown). Together, these
results indicate that the P2 molecules are distributed around the
virion surface. This also explains the need of high antibody
concentrations for inactivation of the virus but low concentrations for
its aggregation.
Previous virus disruption studies suggested that protein P2 is
associated with the phage membrane while the major capsid protein P3
and a minor protein P5 are released as soluble proteins (2). However, P2 could be dissociated from the virion by heat, high pH, or
low SDS concentrations, and thus, a peripheral membrane association was
suggested (17). Recent studies revealed that on mutant
particles lacking the pentameric vertex protein P31, proteins P2 and P5
were also missing (45). To further characterize the
suggested P2 membrane association, we determined the distribution of
the fivefold vertex proteins (P31, P5, and P2; 45)
in sucrose gradient fractions of disrupted phage particles by using
specific antisera. Under the centrifugation conditions (2)
used, phage membrane aggregates sedimented to the bottom of the tube
whereas released proteins remained at the top of the gradient. Under
these conditions, intact virus particles formed a single sedimenting zone. When virus disruption was performed in phosphate buffer, both P2
and P31 were found in the membrane fraction while P3 and P5 remained at
the top (Fig. 6C; 4). In Tris buffer, P2 and P31
were also detached from the membrane and behaved like soluble proteins
in rate zonal centrifugation (Fig. 6C). Together, these results and
studies on the capsid fivefold organization (45) indicate
that P2 and P31 are in contact with the phage membrane. Since P2 seems
to be a soluble protein, its association with the membrane most
probably occurs via interaction with P31.
Both empty and DNA-containing PRD1 particles bind irreversibly to the cell surface. The phage-receptor interaction is classically considered to occur in two steps: (i) recognition and binding and (ii) transformation of this interaction to the DNA penetration step. The binding of the PRD1 adsorption protein P2 to cells was found to be reversible (see determination of the binding constant). However, PRD1 virions bound to the host cannot be detached from the cells under the conditions studied. In LB medium, after 15 min of adsorption and four subsequent extended washing steps (incubation for 30 min at 22°C), about 65% of both empty and DNA-containing phage particles were associated with cells (data not shown), suggesting that virions are irreversibly bound. Also, if a reversible complex exists between the phage and its receptor, one might expect this complex to be dissociated by a high salt concentration. No significant release of either empty or filled particles adsorbed to cells could be detected when increasing amounts of NaCl (up to a 500 mM final concentration) were added after the adsorption period of 15 min (data not shown). Since empty phage particles are as tightly bound to the cells as are the DNA-containing particles, we conclude that in PRD1 infection, DNA penetration is not a prerequisite for irreversible binding.
| |
DISCUSSION |
|---|
|
|
|---|
Recombinant P2 can be produced as a stable, biologically active monomer. By estimating the protein concentration of the 35S-labeled P2 preparation and subsequently measuring the amount of label associated with a defined number of cells, we can calculate the number of P2 molecules bound per cell. Taking into account the number of receptors in RP4-containing cells, a very low number of P2 molecules (close to one) per receptor is obtained. This is consistent with a model in which one P2 molecule mediates the connection between the phage and its receptor.
The anti-P2 serum readily aggregated PRD1 particles. This is in accordance with the idea that protein P2 has a distal location in the spike complex. On the other hand, virus disruption studies revealed that spike complex proteins P31 and P2 are associated with the membrane while the shell composed of major capsid protein P3 is dissociated. It appears that association of the receptor recognition-DNA injection device with the membrane (at the vertices) is independent of the viral protein shell. This is also supported by the previous report that removal of the viral membrane with detergents leaves the protein shell intact except that the fivefold structures are removed with the membrane (15, 34). Recent studies on the organization of the capsid fivefold spike complex indicated that the main protein involved in the DNA packaging, P9, does not interact with the adsorption spike structure (45). These results are consistent with a model in which the DNA packaging machinery occupies a particular vertex of the virion, the remaining 11 vertices being occupied by the spike structure. We cannot, however, exclude the possibility that all of the vertices are identical but with independent DNA packaging and injecting machineries. The latter possibility is less favored based on comparisons to other dsDNA phage packaging systems, in which a multiprotein complex is associated with a specific vertex (28). Both models imply, if P2 is considered as a monomer, either 11 or 12 copies of P2 per virion, values very close to the stoichiometry of 10 determined biochemically by Davis et al. (21).
The two P2-deficient mutants studied, sus170 and sus539, package DNA and do not lack any other structural protein. In Tris buffer (but not in phosphate buffer), these purified mutant particles, unlike the wild-type particles, spontaneously eject DNA and display the tail-like structure presumably involved in DNA ejection (33). Tris buffer destabilizes membranes. This effect was also observed in the virus disruption studies. Removal of P2 apparently allows Tris molecules to gain access to the phage membrane, triggering DNA ejection and tail tube formation.
The above observations can be extended into a model in which protein P2 secures the DNA injection process. Most probably, the association of P2 with the receptor signals, possibly by P2 removal, the activation of the injection process. This P2-receptor association leads to irreversible binding and is independent of the DNA content of the virion, as empty phage particles were found to be as tightly bound to the cells, as were the DNA-containing particles. The tail-like structure is most probably involved in the stabilization of the virus-cell contact. The tail formation is dependent on several phage-encoded proteins, and the involvement of P18 has been previously reported (2). Also, a mutation in gene XXXI prevents tail tube formation and results in loss of the capsid fivefold structure (proteins P2, P5, and P31) and the peripentonal trimers of major capsid protein P3 (45). Since the tail-like structure is readily observed in the P2-deficient mutant, it is likely that P5 and/or P31 contribute to its formation. A noteworthy consequence of this model of DNA injection is that the tail structure would extrude through the particular vertex that makes the contact with the receptor. This mechanism would differ from that of other dsDNA phages, in which the DNA entry and exit vertices are the same, but might be more similar to the one used by adenoviruses, in which all of the fivefold structures are metastable. If there were a specific ejection vertex, the receptor binding should lead to a complex signalling and orientation procedure to ascertain that the tail is ejected toward the cell surface.
| |
ACKNOWLEDGMENTS |
|---|
We are grateful to Marja-Leena Perälä for her skillful technical assistance. We also thank Nisse Kalkkinen for the N-terminal amino acid sequencing of P2 and Erich Lanka for the RP4 clones. The help of Hans van der Zandt in the analytical ultracentrifugation experiments is gratefully acknowledged.
The electron microscopy was performed at the electron microscopy unit, Institute of Biotechnology, University of Helsinki. This investigation was supported by research grants 37725 and 41400 from the Finnish Academy of Sciences.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Biocenter 2, P.O. Box 56, FIN-00014 University of Helsinki, Finland. Phone: 358-9-70859100. Fax: 358-9-70859098. E-mail: gen_phag{at}cc.helsinki.fi.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Balzer, D.,
G. Ziegelin,
W. Pansegrau,
V. Kruft, and E. Lanka.
1992.
KorB protein of promiscuous plasmid RP4 recognizes inverted sequence repetitions in regions essential for conjugative plasmid transfer.
Nucleic Acids Res.
20:1851-1858 |
| 2. |
Bamford, D., and L. Mindich.
1982.
Structure of the lipid-containing bacteriophage PRD1: disruption of wild-type and nonsense mutant phage particles with guanidine hydrochloride.
J. Virol.
44:1031-1038 |
| 3. | Bamford, D. H., J. Caldentey, and J. K. H. Bamford. 1995. Bacteriophage PRD1: a broad host range dsDNA Tectivirus with an internal membrane. Adv. Virus Res. 45:281-319[Medline]. |
| 4. |
Bamford, D.,
T. McGraw,
G. MacKenzie, and L. Mindich.
1983.
Identification of a protein bound to the termini of bacteriophage PRD1 DNA.
J. Virol.
47:311-316 |
| 5. |
Bamford, D. H., and L. Mindich.
1984.
Characterization of the DNA-protein complex at the termini of the bacteriophage PRD1 genome.
J. Virol.
50:309-315 |
| 6. |
Bamford, D. H.,
M. Romantschuk, and P. Somerharju.
1987.
Membrane fusion in prokaryotes: bacteriophage 6 membrane fuses with the Pseudomonas syringae outer membrane.
EMBO J.
6:1467-1473[Medline].
|
| 7. |
Bamford, D. H.,
L. Rouhiainen,
K. Takkinen, and H. Söderlund.
1981.
Comparison of the lipid containing bacteriophages PRD1, PR3, PR4, PR5 and L17.
J. Gen. Virol.
57:365-373 |
| 8. | Bamford, J. K. H., and D. H. Bamford. 1990. Capsomer proteins of bacteriophage PRD1, a bacterial virus with a membrane. Virology 177:445-451[Medline]. |
| 9. | Bamford, J. K. H., A.-L. Hänninen, T. M. Pakula, P. M. Ojala, N. Kalkkinen, M. Frilander, and D. H. Bamford. 1991. Genome organization of membrane-containing bacteriophage PRD1. Virology 183:658-676[Medline]. |
| 10. | Benson, S. D., J. K. H. Bamford, D. H. Bamford, and R. Burnett. 1999. Viral evolution revealed by bacteriophage PRD1 and human adenovirus coat protein structures. Cell 98:825-833[Medline]. |
| 11. |
Bordier, C.
1981.
Phase separation of integral membrane proteins in Triton X-114 solution.
J. Biol. Chem.
256:1604-1607 |
| 12. | Bradford, M. M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248-254[Medline]. |
| 13. | Bradley, D. E. 1980. Morphological and serological relationship of conjugative pili. Plasmid 4:155-169[Medline]. |
| 14. | Bradley, D. E., and E. L. Rutherford. 1975. Basic characterization of lipid-containing bacteriophage specific for plasmids of the P, N and W compatibility groups. Can. J. Microbiol. 21:152-163[Medline]. |
| 15. | Butcher, S. J., D. H. Bamford, and S. D. Fuller. 1995. DNA packaging orders the membrane of bacteriophage PRD1. EMBO J. 14:6078-6086[Medline]. |
| 16. |
Caldentey, J.,
L. Blanco,
D. H. Bamford, and M. Salas.
1993.
In vitro replication of bacteriophage PRD1 DNA. Characterization of the protein-primed initiation site.
Nucleic Acids Res.
21:3725-3730 |
| 17. | Caldentey, J., C. Luo, and D. H. Bamford. 1993. Dissociation of the lipid-containing bacteriophage PRD1: effects of heat, pH, and sodium dodecyl sulfate. Virology 194:557-563[Medline]. |
| 18. |
Campbell, J. L.,
C. C. Richardson, and F. W. Studier.
1978.
Genetic recombination and complementation between bacteriophage T7 and cloned fragments of T7 DNA.
Proc. Natl. Acad. Sci. USA
75:2276-2280 |
| 19. |
Datta, N.,
R. W. Hedges,
E. J. Shaw,
R. B. Sykes, and M. H. Richmond.
1971.
Properties of an R factor from Pseudomonas aeruginosa.
J. Bacteriol.
108:1244-1249 |
| 20. |
Daugelavi ius, R.,
J. K. H. Bamford,
A. M. Grahn,
E. Lanka, and D. H. Bamford.
1997.
IncP plasmid encoded cell envelope-associated DNA transfer complex increases the cell permeability.
J. Bacteriol.
179:5195-5202 |
| 21. | Davis, T. N., E. D. Muller, and J. E. Cronan, Jr. 1982. The virion of the lipid-containing bacteriophage PR4. Virology 120:287-306[Medline]. |
| 22. |
Dreiseikelmann, B.
1994.
Translocation of DNA across bacterial membranes.
Microbiol. Rev.
58:293-316 |
| 23. | Dunn, J. J., and F. W. Studier. 1983. Complete nucleotide sequence of bacteriophage T7 genetic elements. J. Mol. Biol. 166:477-535[Medline]. |
| 24. | Garnier, J., D. J. Osguthorpe, and B. Robson. 1978. Analysis of the accuracy and implications of simple methods for predicting the secondary structure of globular proteins. J. Mol. Biol. 120:97-120[Medline]. |
| 25. | Grahn, A. M., J. Haase, D. H. Bamford, and E. Lanka. Components of the RP4 conjugative transfer apparatus form an envelope structure bridging inner and outer membranes of donor cells: implications for related macromolecule transport systems. Submitted for publication. |
| 26. |
Grahn, A. M.,
J. Haase,
E. Lanka, and D. H. Bamford.
1997.
The assembly of a functional phage PRD1 receptor depends on 11 genes of the IncP plasmid mating pair formation complex.
J. Bacteriol.
179:4733-4740 |
| 27. |
Haase, J.,
R. Lurz,
A. M. Grahn,
D. H. Bamford, and E. Lanka.
1995.
Bacterial conjugation mediated by plasmid RP4: RSF1010 mobilization, donor-specific phage propagation, and pilus production require the same Tra2 core components of a proposed DNA transport complex.
J. Bacteriol.
177:4779-4791 |
| 28. | Hendrix, R. 1998. Bacteriophage DNA packaging: RNA gears in a DNA transport machine. Cell 94:147-150[Medline]. |
| 29. |
Kenney, J. M.,
J. Hantula,
S. D. Fuller,
L. Mindich,
P. M. Ojala, and D. H. Bamford.
1992.
Bacteriophage 6 envelope elucidated by chemical crosslinking, immunodetection, and cryoelectron microscopy.
Virology
190:635-644[Medline].
|
| 30. |
Kotilainen, M. M.,
A. M. Grahn,
J. K. H. Bamford, and D. H. Bamford.
1993.
Binding of an Escherichia coli double-stranded DNA virus PRD1 to a receptor coded by an IncP-type plasmid.
J. Bacteriol.
175:3089-3095 |
| 31. |
Lessl, M.,
D. Balzer,
K. Weyrauch, and E. Lanka.
1993.
The mating pair formation system of plasmid RP4 defined by RSF1010 mobilization and donor-specific phage propagation.
J. Bacteriol.
175:6415-6425 |
| 32. | Lessl, M., and E. Lanka. 1994. Common mechanisms in bacterial conjugation and Ti-mediated T-DNA transfer to plant cells. Cell 77:321-324[Medline]. |
| 33. |
Lundström, K. H.,
D. H. Bamford,
E. T. Palva, and K. Lounatmaa.
1979.
Lipid-containing bacteriophage PR4: structure and life cycle.
J. Gen. Virol.
43:583-592 |
| 34. | Luo, C., S. Butcher, and D. H. Bamford. 1993. Isolation of a phospholipid-free protein shell of bacteriophage PRD1, an Escherichia coli virus with an internal membrane. Virology 194:564-569[Medline]. |
| 35. | Lyra, C., H. Savilahti, and D. H. Bamford. 1991. High-frequency transfer of linear DNA containing 5'-covalently linked terminal proteins: electroporation of bacteriophage PRD1 genome into Escherichia coli. Mol. Gen. Genet. 228:65-69[Medline]. |
| 36. |
Mindich, L.,
D. Bamford,
C. Goldthwaite,
M. Laverty, and G. MacKenzie.
1982.
Isolation of nonsense mutants of lipid-containing bacteriophage PRD1.
J. Virol.
44:1013-1020 |
| 37. |
Mindich, L.,
D. Bamford,
T. McGraw, and G. MacKenzie.
1982.
Assembly of bacteriophage PRD1: particle formation with wild-type and mutant viruses.
J. Virol.
44:1021-1030 |
| 38. |
Mindich, L.,
J. Cohen, and M. Weisburd.
1976.
Isolation of nonsense suppressor mutants in Pseudomonas.
J. Bacteriol.
126:177-182 |
| 39. |
Olkkonen, V. M., and D. H. Bamford.
1989.
Quantitation of the adsorption and penetration stages of bacteriophage 6 infection.
Virology
171:229-238[Medline].
|
| 40. |
Olkkonen, V. M.,
P. M. Pekkala, and D. H. Bamford.
1988.
Monoclonal antibodies to the major structural proteins of bacteriophage 6.
Virology
165:317-320[Medline].
|
| 41. |
Olsen, R. H.,
J.-S. Siak, and R. H. Gray.
1974.
Characteristics of PRD1, a plasmid-dependent broad host range DNA bacteriophage.
J. Virol.
14:689-699 |
| 42. | Pansegrau, W., and E. Lanka. 1996. Enzymology of DNA transfer by conjugative mechanisms. Prog. Nucleic Acid Res. 54:197-251[Medline]. |
| 43. | Pansegrau, W., E. Lanka, P. T. Barth, D. H. Figurski, D. G. Guiney, D. Haas, D. Helinski, H. Schwab, V. A. Stanisich, and C. M. Thomas. 1994. Complete nucleotide sequence of Birmingham IncP plasmids: compilation and comparative analysis. J. Mol. Biol. 239:623-663[Medline]. |
| 44. | Poranen, M. M., R. Daugelavi ius, P. M. Ojala, and D. H. Bamford. A novel virus-host cell membrane
interaction; membrane voltage dependent endocytic-like entry of
bacteriophage 6 nucleocapsid. J. Mol. Biol. 291:575-587.
|
| 45. | Rydman, P. S., J. Caldentey, S. J. Butcher, S. D. Fuller, T. Rutten, and D. H. Bamford. Bacteriophage PRD1 contains a five-fold receptor-binding structure similar to that of adenovirus. Submitted for publication. |
| 46. | Salas, M. 1991. Protein-priming of DNA replication. Annu. Rev. Biochem. 60:39-71[Medline]. |
| 47. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y |
| 48. | Savilahti, H., and D. H. Bamford. 1986. Linear DNA replication: inverted terminal repeats of five closely related Escherichia coli bacteriophages. Gene 49:199-205[Medline]. |
| 49. |
Savilahti, H.,
J. Caldentey,
K. Lundström,
J. E. Syväoja, and D. H. Bamford.
1991.
Overexpression, purification, and characterization of Escherichia coli bacteriophage PRD1 DNA polymerase. In vitro synthesis of full-length PRD1 DNA with purified proteins.
J. Biol. Chem.
266:18737-18744 |
| 50. | Stewart, P. L., S. D. Fuller, and R. M. Burnett. 1993. Different imaging of adenovirus: bridging the resolution gap between X-ray crystallography and electron microscopy. EMBO J. 12:2589-2599[Medline]. |
| 51. | Stewart, P. L., S. Ghosh, D. H. Bamford, and R. M. Burnett. 1993. Crystallization of the major coat protein of PRD1, a bacteriophage with an internal membrane. J. Mol. Biol. 230:349-352[Medline]. |
| 52. |
van Oostrum, J., and R. M. Burnett.
1985.
Molecular composition of the adenovirus type 2 virion.
J. Virol.
56:439-448 |
| 53. | Walin, L., R. Tuma, G. J. Thomas, Jr., and D. H. Bamford. 1994. Purification of viruses and macromolecular assemblies for structural investigations using a novel ion exchange method. Virology 201:1-7[Medline]. |
| 54. |
Waters, V. L.,
B. Strack,
W. Pansegrau,
E. Lanka, and D. G. Guiney.
1992.
Mutational analysis of essential IncP plasmid transfer genes traF and traG and involvement of traF in phage sensitivity.
J. Bacteriol.
174:6666-6673 |
| 55. | Zechner, E. L., F. de la Cruz, R. Eisenbrandt, A. M. Grahn, G. Koraimann, E. Lanka, G. Muth, W. Pansegrau, C. M. Thomas, C. M. Wilkins, and M. Zatyka. Conjugative DNA transfer processes. In C. M. Thomas (ed.), The horizontal gene pool: bacterial plasmids and gene spread, in press. Harwood Academic Publishers GmbH, Amsterdam, The Netherlands. |
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||